Indian stock indexes fell early Wednesday, Nov. 18, while shares in Caplin Point Laboratories Limited declined a day after the company disclosed a U.S. Food and Drug Administration (FDA) inspection classification.
At 11:06 p.m. ET Tuesday (04:06 UTC Wednesday), Upstox, citing exchange data, put the Sensex at 82,258.43, a loss of 273.76 points, and the Nifty 50 at 25,293.65, down 93.75 points. The benchmarks track 30 stocks on India’s BSE and 50 on its National Stock Exchange, respectively. The readings were from morning trading, not the close.
Individual shares moved in different directions. NDTV Profit reported IIFL Finance Limited up 5% and Caplin Point down 6% in early trading. Upstox separately reported that IIFL shares had climbed as much as 6.37% to ₹676.95.
Caplin Point’s Nov. 17 exchange filing said the FDA assigned an “Official Action Indicated” classification to its inspection of the Gummidipoondi facility operated by subsidiary Caplin Steriles Limited. Inspectors made 10 observations during their Aug. 13-21, 2026, visit, and the company received the classification Nov. 16. Caplin Point said production and shipments continued and that it did not expect a significant effect on its finances or operations.
FDA guidance describes the classification as a finding of unacceptable compliance for which regulatory or administrative measures are recommended. The label does not establish that the agency has taken a separate enforcement step.
Elsewhere in the market, Upstox quoted January Brent futures at $92.69 a barrel at 11:19 p.m. ET Tuesday (04:19 UTC Wednesday). The International Energy Agency forecast that global oil supply would exceed demand in the fourth quarter of 2026, while identifying attacks on shipping as a continuing risk.
U.S. chipmaker Nvidia reported $115.8 billion in revenue for its fiscal third quarter ended Oct. 25, up 103% from a year earlier. It projected fiscal fourth-quarter revenue of $130 billion, plus or minus 3%.



